A placebo-controlled randomised trial to assess the effect of TGF-ß1-expressing chondrocytes in patients with arthritis of the knee

Bone and Joint Journal

Volumn 97-B, Issue 7, 2015, Pages 924-932

  Lee, M C ^a   Ha, C W ^a,b   Elmallah, R K ^a   Cherian, J J ^a   Cho, J J ^a   Kim, T W ^a,d   Bin, S I ^a,e   Mont, M A ^a,c  

^a Seoul National University Hospital   (South Korea)

^b Samsung Medical Center   (South Korea)

^c SINAI HOSPITAL OF BALTIMORE   (United States)

^d Kolon Life Science Inc   (South Korea)

^e Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TISSUEGENE C; UNCLASSIFIED DRUG; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE REGENERATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENETIC ENGINEERING; HUMAN; INJECTION; INJECTION SITE EDEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; JOINT SWELLING; KNEE INJURY AND OSTEOARTHRITIS OUTCOME SCORE; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PAIN SEVERITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGENERATION; SWELLING; VISUAL ANALOG SCALE; BIOSYNTHESIS; CLINICAL TRIAL; DAILY LIFE ACTIVITY; INTRAARTICULAR DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; OSTEOARTHRITIS, KNEE; PHASE 2 CLINICAL TRIAL; SINGLE BLIND PROCEDURE; TRANSPLANTATION;

ACTIVITIES OF DAILY LIVING; AGED; CHONDROCYTES; FEMALE; HUMANS; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; QUALITY OF LIFE; SINGLE-BLIND METHOD; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84937546789     PISSN: 20494394     EISSN: 20494408     Source Type: Journal    
DOI: 10.1302/0301-620X.97B7.35852     Document Type: Article

References (30)

1. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-1049.
2. Loeser RF Jr. Aging and the etiopathogenesis and treatment of osteoarthritis. Rheum Dis Clin North Am 2000;26:547-567.
3. Hunter DJ. Osteoarthritis. Best Pract Res Clin Rheumatol 2011;25:801-814.
4. Abrams GD, Frank RM, Fortier LA, Cole BJ. Platelet-rich plasma for articular cartilage repair. Sports Med Arthrosc 2013;21:213-219.
5. Perera JR, Jaiswal PK, Khan WS. The potential therapeutic use of stem cells in cartilage repair. Curr Stem Cell Res Ther 2012;7:149-156.
6. Ha CW, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy 2012;14:247-256.
7. Lee DK, Choi KB, Oh IS, et al. Continuous transforming growth factor beta1 secretion by cell-mediated gene therapy maintains chondrocyte redifferentiation. Tissue Eng 2005;11:310-318.
8. Abe T, Yamada H, Nakajima H, et al. Repair of full-thickness cartilage defects using liposomal transforming growth factor-beta1. J Orthop Sci 2003;8:92-101.
9. Riera KM, Rothfusz NE, Wilusz RE, et al. Interleukin-1, tumor necrosis factoralpha, and transforming growth factor-beta 1 and integrative meniscal repair: influences on meniscal cell proliferation and migration. Arthritis Res Ther 2011;13:R187.
10. Singh A, Goel SC, Gupta KK, et al. The role of stem cells in osteoarthritis: An experimental study in rabbits. Bone Joint Res 2014;3:32-37.
11. Civinini R, Nistri L, Martini C, et al. Growth factors in the treatment of early osteoarthritis. Clin Cases Miner Bone Metab 2013;10:26-29.
12. van Bergen CJ, Kerkhoffs GM, Özdemir M, et al. Demineralized bone matrix and platelet-rich plasma do not improve healing of osteochondral defects of the talus: an experimental goat study. Osteoarthritis Cartilage 2013;21:1746-1754.
13. Noh MJ, Copeland RO, Yi Y, et al. Pre-clinical studies of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 (TG-C). Cytotherapy 2010;12:384-393.
14. van den Borne MP, Raijmakers NJ, Vanlauwe J, et al. International Cartilage Repair Society (ICRS) and Oswestry macroscopic cartilage evaluation scores validated for use in Autologous Chondrocyte Implantation (ACI) and microfracture. Osteoarthritis Cartilage 2007;15:1397-1402.
15. Hefti F, Müller W, Jakob RP, Stäubli HU. Evaluation of knee ligament injuries with the IKDC form. Knee Surg Sports Traumatol Arthrosc 1993;1:226-234.
16. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502.
17. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-1840.
18. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes 2003;1:64.
19. No authors listed. What is a Serious Adverse Event? U. S. Food and Drug Administration. http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm (date last accessed 20 March 2015).
20. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest 1994;71:279-290.
21. Matsumoto K, Matsunaga S, Imamura T, et al. Expression and distribution of transforming growth factor-beta and decorin during fracture healing. In Vivo 1994;8:215-219.
22. Sporn MB, Roberts AB. Peptide growth factors are multifunctional. Nature 1988;332:217-219.
23. Trippel SB. Growth factors as therapeutic agents. Instr Course Lect 1997;46:473-476.
24. Insall JN, Dorr LD, Scott RD, Scott WN. Rationale of the Knee Society clinical rating system. Clin Orthop Relat Res 1989;248:13-14.
25. Giatsidis G, Dalla Venezia E, Bassetto F. The role of gene therapy in regenerative surgery: updated insights. Plast Reconstr Surg 2013;131:1425-1435.
26. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-1009.
27. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977;18:481-491.
28. Qi Y, Feng G, Yan W. Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis. Mol Biol Rep 2012;39:5683-5689.
29. Centeno CJ, Busse D, Kisiday J, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician 2008;11:343-353.
30. Filardo G, Kon E, Buda R, et al. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2011;19:528-535.